American Journal of Kidney Diseases 1999: Vol 34 Index

47 Pages·1999·13.1 MB·English

AUTHOR INDEX
Chandler, G., $2:40 Dominguez-Cabrera, C., 508 Fukushima, K., 1016
Chang, S.-K., 259 Domrongkitchiaporn, S., 29 Furuta, T., 894
Charra, B., 597 Donadio, J. V., Jr., 549
Chauveau, P., 500 Dong, Y., 583
Gabow, P. A., 120, 639, 4:E17, 863
ChazaJn., A ., 14 Duley, I., 863
Gallo, G., 884
Chew, 'S. T. H., 135 Dunfee, T. P., 222
Gan, B. S., 932
Chiba, S., 894 Dunn, S. R., 818
Garcia, C., 264
Chiu, M. Y., 540 Dydak, U., 875
Garcia, J., 43
Choi, J.-S., 259 Dysseleer, A., 166
Garcia-Buela, J., 824
Chot, Po €. L., 3:-E12
Garg, K., 120
Choi, Y.-J., 5:E22 Ebben, J. P., 1065 Gaughan, W. J., 4:E16
Choudhury, S., 869
Elinder, C.-G., 1083 Geadah, D., 486
Cline, K. N., 713 Elston, O., S2:40 Gelfand, E., 65
Clutterbuck, E., 155 Eltayeb, B. O., 818 Gerakis, A., 521
Coimbra, T. M., 328 Emerson, S., 688 Germino, G. G., 1152
Collins, A. J., 1065 Emoto, M., 832 Ghiggeri, GM., 1048
Combarnous, F., 839 Engels, K., 228 Ghio, L., 1048
Combe, C., 500 Erbas, B., 140 Giacchetti, G., 1002
Comerford, S. A., 180 Ethier, J., 125 Ginevri, F., 1048
Compte, T., 264 Eto, T., 114 Girgis, [., 1105
Connors, A. F., Jr., 706
Everson, S. E., 1065 Gitomer, J. J., 1:E2, 2:E2, 3:E8,
Conrad, K. P., 1142
4:E15, 5:E19, 6:E24
Constantini, E. G., 1065
Fainaru, M., 438 Glynne, P., 155
Constantino, T., 1105
Contoreggi, C. S., 207 Faraggiana, T., 85 Godwin, D. A., 651
Farina, M., 618 Goffin, E., 166
Contreras, G., 1105
Cooney, S. K., 918 Fassi, A., 626 Goldsmith, D., 155
Feigin, M., 1129 Goldstein, C. S., 588
Cordido, F., 824
Cosby, R. L., 304 Feinfeld, D. A., 702 Goldstein, S. L., 49
Felsenfeld, A. J., 456 Gomez-Garcia, L., 338
Cosio, F. G., 731
Ferder, L., 445 Gonzalez-Roncero, F., 338
Ferguson, R. M., 731 Goto, M., 845
Cosyns, J.-P., 166
Feriozzi, S., 85 Goumenos, D., 521
Courteau, S., 486
Fernandez-Rodriguez, A. M., 508 Grassi, C., 618
Courvoisier, S., 745
Fervenza, F. C., 549 Grcevska, L., 911
Criswell, L. A., 1040
Crowley, S. T., 161 Fiacco, V., 464 Green, M., 438
Fick-Brosnahan, G., 639, 4:E17 Greer, J. W., S1:1
Cunniff, P. J., 349
Fink, J. C., 1, 694 Grimm, E. M., 1:E2. 2:E2, 3:E8,
Curtis, J. J., 756, 869
Finkel, K. W., 1:E2, 2:E2, 3:E8, 4:E15, 5:E19, 6:E24
4:E15, 5:E19, 6:E24 Gruenhagen, S. E., 324
D’ Agati, V. D., 184, 588 Finkelstein, F. O., 752 Gualberti, L., 1105
Daha, M. R., 344 Fioretto, P., 1002 Gude, F., 996
Dall’ Amico, R., 1048 Fischer, F.-P., 678 Guignard, J.-P., 2:E3
Darnell, A., 273 Fishbane, S., $2:47 Guillevin, L., 633
Daskal, I., 5:E21 Fitzwilliam, J., 135 Guindeo-Casastis, M. C., 508
Davis, C. L., 405 Flanders, W. D., 1075 Gulati, S., 646
Davis, J. L., 212 Flores-Suarez, L. F., 364 Giinther, E., 150
Deacon, A., 155 Fogo, A. B., 1:E1, 2:E1, 3:E7, 768, Gupta, A., 646
De Cavanagh, E. M. V., 445 4:E14, 5:E18, 5:liv, 6:E23 Gupta, K. L., 6:E25
Deenitchina, S. $., 279 Foran, M. P., 824 Giirgiin, C., 218
DeFranco, P., 65 Fouque, D., 839 Gutierrez, C., 264
Delawari, E., 839 Fraga, C. G., 445
Delclaux, C., 500 Frankel, W. L., 731 Ha, K.-S., 259
Delmez, J., 493 Frankenfield, D. L., 721, S2:5, 1075 Haag-Weber, M., 247
Depner, T. A., 493 Frederick, P. R., 721, 1075 Haas, M., 69, 540
De Précigout, V., 500 Freedman, B. I., 254 Hakim, R., 471
Deteix, P., 633 Frey, F. J., 569 Halimi, S., 795
Di Cataldo, A. 98 Friedman, E. A., 775 Hamm, L. L., 960
Dickey, K. W., 752 Friedman, G., 65 Hammer, R. E., 180
Djurdjev, O., 125 Frinak, S., 21 Hansen, C., 651
Dolfin, T., 1129 Fujimoto, S., 114 Hanson, J., S1:1
Domico, J., 228 Fujishima, M., 279, 1096 Hao, W., 1065
1162 AUTHOR INDEX
Hara, S., 926 Jakob, S., 569 Lafferty, J., 1105
Harchowal, J., $2:40 James, L. R., 932 Lai, F. M.-M., 3:E12
Hassan, M. H., 4:E16 Jeffrey, R., 937 Lai, K.-N., 235, 380, 1056, 6:E26
Hebert, L. A., 308 Jha, V., 6:E25 Lai, L.-W., 378
Hegewisch-Becker, S., 5:E20 Jiménez, A., 43 Lajoie, G., 932
Heidland, A., 433 Jindal, K., 125 Lam, C. C. K., 889
Heimbiirger, O., 947, 1083 Jirakranont, B., 29 Larroche, C., 633
Heinzelmann, M., 384 Johnson, A. M., 120, 639, 4:E17, 863 Lasne, Y., 839
Helgerson, S. D., 1075 Johnson, C. A., 657, $2:5 PaCS. 315
Henry, M. L., 731 Jones, C.A;,'S1:1 Laville, M., 839
Hercz, G., 688 Josephson, M. A., 69, 540 Law, M.-C., 235, 1056
Hermans, C., 166 Joshi, K., 6:E25 Leblanc, M., 486
Herzenberg, A. M., 560 Juillard, L., 838 Lee, H.'S., 1:E3
Hess, J. M., 207 Junaid, S. M. A., 92 Lee, H.-A., 259
Hino, S., 1016 Lee; K.. C., 355
Hirakata, E., 1096 ee, Ss MLK. 565
Kahn, S. [., 14
Hirakata, H., 279, 1096 Lehmann, H., 364
Kaiser, J. W., 21
Hirano, K., 902 Leung, C. B., 514, 3:E12, 1056, 1132
Kaneko, K., 170
Hirano, T., 279 Levey, A. S., 308
Kaplan, B., 65
Hirth, R., S1:1 Levin, A., 125
Kara, N., 140
Hisanaga, S., 114 Levin, N. W., 493
Kasiske, B., 884
Ho; ‘CP. G:E27 Levine, D. Z., 759
Katafuchi, R., 279
Hoen, B., $2:30 Levine, J. S., 3:E11
Katori, H., 926
Holden, J. K., 560 Levinksy, N. G., 775
Katz, O., 146
Holman, D’A., 1033 Lewis, E. J., 308, 809, 818
Katzir, Z., 146, 438
Hong, S.-Y., 259 Lewis, J. B., 308, 768, 809
Kausz, A. T., 651, 688
Horl, W. H., 247, $2:25 Lewis, R. M., 869
Kawahara, H., 170
Hortal-Cascon, L., 508 Ge sisa5
Kawamoto, M., 114
Horvath, F., Jr., 966 Li, F. K., 6:E26
Kawamura, T., 902
Hosoya, T., 902 LasPoK. 12353914, 10562 1132
Kay, A., 405
Hossfeld, D. K., 5:E20 Lien, Y.-H. H., 378
Keane, W. F., 2:xliii
Hotta, O., 894 Light, P. D., 694
Kelley, V. R., 761
Houri, C., 1129 Lijima, K., 289
Kew, J., 3:E12
Hovick, E. T., 1089 Lilaj, T., 247
Khajehdehi, P., 92
Hudson, B. G., 549 Lindholm, B., 1083
Khaodhiar, L., $2:35
Hulbert-Shearon, T., S1: Li Volti, S., 98
Ka, PK. T.; 3:B12
Hull, S., 36 Lobo, P. I., 706
Kim, C. W., 1:E3
Hunchik, M., 1125 Locatelli, F., 795
Kam, J.'S., 3:E13
Lépez-Hidalgo, R., 338
Hyndman, M. E., 669 Kim, J. Y., 1:E3 Lui, S. L., 889
Kinoshita, H., 114
Lynn, M. L., 61
Kitamura, K., 114
laina, A., 146 Kiyohara, Y., 279
Ibayashi, S., 1096
Kleiner, M., 1105 Ma, J. Z., 1065
lijima, K., 854 Kobayashi, S., 3:E10 Maaz, D., 14
Ikizler, T. A., 471 Kocak, H., 140 Maccario, M., 530
Imai, H., 902 Kohli, H. S., 6:E25 McClellan, W. M., 721
Imai, T., 926 Kopp, J. B., 177 McCue, P. A., 4:E16
Indridason, O. S., 135 Korbet, S. M., 713 McDonald, J. C., 61
Inoue, S., 926 Korzets, Z., 1129 Macdougall, I. C., 2:40
Inoue, Y., 289, 854 Kosorok, M. R., 657 McGowan, T. A., 818
Inserra, F., 445 Kotaki, S., 170 MacGregor, G. A., 583
Iqbal, A
Kotani, M., 845 Macia, M., 43
Isaacs, R. B., 706 Kovacs, B., 5:E21 McMillan, R. W., 61
Ishida, A., 3:E10 Kovalik, E. C., 135 Magil, A. B., 560
Ishida, I., 1096 Kubo, M-a., 1096 Magnusen, H. M., 324
Ismail-Beigi, F., 189
Kuhlmann, U., 678 Mailloux, L. U., 359
Itin, P., 745 Kurnik, B. R. C., 1010 Maioli, M., 1002
Kurth, S. J., 694 Malhotra, D., 304
Jaber, B. L., 349 Kurtzman, N. A., 1137 Manco-Johnson, M., 120
Jacobs, M. G., 65 Kuzuhara, K., 926 Manns, B. J., 669
Jain, A., S1:1 Kwong, Y. L., 889 Manor, Y., 1129
AUTHOR INDEX
Mantero, F., 1002 Nakao, K., 845 Perez, G., 1105
Markowitz, G. S., 184, 588 Nanhou, A., 364 Pérez-Borges, P., 508
Marks, E. A., 565 Nass, K., 955 Pérez-Oller, L., 273
Marti, H.-P., 569 Navarro, J. F., 43 Perico, N., 626
Martin, B. R., 324 Navarro, M., 338 Pesavento, T. E., 731
Martin-Herrera, C., 338 Neugarten, J., 884 Peterson, D. D., 1089
Martin-Malo, A., 456 Neumayer, H.-H., 556, 3:E9 Petronis, J. D., 207, 341
Martinez-Vea, A., 264 Newman, N., 464 Pfister, M., 569
Maruyama, K., 1016 Nickeleit, V., 1146 Pierratos, A., 597
Maruyama, N., 902 Niederer, U., 569 Piette, J. C., 633
Matas, Z., 438 Nishio, H., 854 Pirsch, J., 869
Matos, V., 2:E3 Nishiyama, J-i., 3:E10 Pirson, Y., 166
Matsushita, Y., 926 Nishiyama, K., 289, 854 Pittala, D., 98
Matzke, G. R., 203 Nishizawa, Y., 832 Polenakovik, M. H., 911
McClellan, W. M., 1075 Nock, S. L., 706 Pomeranz, A., 1129
McCloughlin, J., 1105 Nosadini, R., 1002 Ponticelli, C., 530, 618
McGinn, T. G., 1105 Nowack, R., 364 Port, F. K., S1:1, 424
Meehan, S. M., 69 Pozzi, C., 618
Mees, E. J. D., 218 Oda, K., 611 Prabhu, P. N., 937
Meier, D., 875 Ogawa, Y., 845 Prajapati, D., 932
Meier-Kriesche, H.-U., 65 Ojo, A. O., S1:1 Pressman, M. R., 1089
Mendelssohn, D., 125 Okada, H., 170 Pugh, J., 721
Mercer-Jones, M. A., 384 Okada, M., 1016 Puhlman, M. E., 918
Messana, J. M., 424 Oliver, J. A., 264 Pupim, L. B., 471
Mettang, T., 678 Omae, T., 1096 Pusey, C., 155
Meyers-Purkiss, A., S1:1 O'Neill, W. C., 955
Meysen, T., 433
Oreopoulos, D. G., 663 Quadri, K., 5 5
Michaux, L., 166 Ornt, D., 493 Quaglini, S., 53 0
Mihatsch, M. J., 745, 1146 Ortner, M.-A., 556 Quan, A., 11 25
Mila, M., 273 Orzol, S., 424
Mir, R., 702 Owen, W., 493
MMiitwtam,a n,M. , N.2,8 91 73 OOzweenn,, SW.,. 1F4.0, Jr., 721, S2:1, §2:5 RRaahgiumsia,, SR..,, 8958
Miyazato, H., 1016 Ozenne, S., 500 Raj, D. S. C., 597
Moberly, J. B., 663 Ozerkan, F., 218 Ram, S. J., 478
Modai, D., 146 Ozkahya, M., 218 Reddy, S. M., 3:E11
Mok, C. C., 315 Regan, F., 207, 341
Molero-Labarta, T., 508 Rehman, S. U., 471
Moll, S., 745, 1146 Padhi, I. D., 222 Reilly, R. F., 161
Pas CYC). 107 Remuzzi, A., 626
Mollica, F., 98
Palmer, R. B., 651 Remuzzi, G., 626, 951
Molony, D. A., 1:E2, 2:E2, 3:E8,
4:E15, 5:E19, 6:E24 Palop-Cubillo, L., 508 Renis, M., 98
Montini, G., 1048 Palumbo, M., 98 Rennke, H. G., 3:E11
Mora, C., 43 Pani, A., 618 Richart, C., 264
Morii, H., 832 Parekh, R., S1:1 Rigalleau, V., 500
Morita, A., 832 Parent, D., 486 Ritz, E., 150, 795
Moriya, H., 3:E10 Parsons, H. G., 669 Rivabella, L., 1048
Moroni, G., 530 Pasquali, Rocco, M. V., 721, 1075
Muda, A. O., 85 Passerini, P., 618 Rocha, J. L., 338
Passmore, J. C., 384 Rodriguez, M., 456
Mukoyama, M., 845
Mulgaonkar, S., 65 Patel, R. V., 222 Rodriguez-Carmona, A., 824
Murakami, R., 289 Patruta, S. 1., $2:25 Rodriguez-Puras, M. J., 338
Myerburg, R. J., 1105 Paueksakon, P., 768 Rohde, R., 818
Pauli-Magnus, C., 678 Rohde, R. D., 308
Paulson, W. D., 478 Rohdes, R. D., 809
Nadeau, J., 768 Peck, L. W., 324 Romeh, S. A., 55
Nagase, M., 611 Pegram, S., 254 Romero, R., 996
Nakabayashi, I., 3:E10 Pei, Y., 688 Roth, S., 150
Nakagawa, M., 845 Peixoto, A. J., 161 Rousset, H., 633
Nakamoto, H., 170 Pelletier, R. P., 731 Rovin, B. H., 761
Nakamura, H., 289, 854 Peralta, C., 264 Roys, E., S1:1
Nakanishi, K., 854 Pereira, B. J. G., 349 Rudolph, B., 556
1164 AUTHOR INDEX
Ruml, L. A., 107 Shirakawa, T., 289, 854 Tesch, G. H., 761
Russo, A., 98 Shoji, T., 832 Thistlethwaite, J. R., 69, 540
Rychlik, I., 795 Short, R., 918 Thomas, M., 1033
Ryuzaki, M., 170 Shortland, J. R., 521 Thomas, S., 678, 1139
Shyr, Y., 471 Thompson, C. R., 125
Sibai-Galland, R., 839 To, K. F, 3:E12
Saad, T. F.,, 1114
Silbiger, S., 884 Tobe, S., 125
Saatci, U., 140
Simpson, P. M., 207 Tokura, T., 114
Saavedra-Santana, P., 508
Sagnella, G. A., 583 Singer, J., 125 Tonolo, G., 1002
Singh, S., 560 Torra, R., 273
St. Pierre, D., 14
Sakai, O., 902 Sklar, A., 464 Torres, A., 43
Sakhuja, V., 6:E25 Smetana, S., 438 Torres, V. E., 6: xlv-xl viii
Salinas-Madrigal, L., 92 Solini,A. , 1002 Touchette, M. A., 222
Saller, A., 1002 Sorkin, M. 1., 228 Townsend, R. R., 120
Sorof, J. M., 49 Toz, H., 218
Samsell, L. S., 228
Samuels, A., 5:E21 Soubrier, M., 633 Tracy, T. S., 228
Sanchez, P., 264 Soucie, J. M., 254 Traeger, J.. 839
Souweine, B., 633 Trendelenburg, M., 745
Sanchez-Guisande, D., 996
Spath, P. J., 745 Truong, L. D., 5:E22
Sardu, C., 1002
Sauron, C., 633 Spencer, C. E., 706 Tsiouris, N., 5:E21
Sawaya, D. E., 61 Spitalewitz, S., 308 Tsujimoto, Y., 832
Sawyer, R., 706 Stack, A., S1:1 Tuncbilek, E., 140
Scalamogna, M., 1048 Stahl, R. A. K., 5:E20 Turner, M. S., 694
Schaefer, J. P., 669 Stamm, E. R., 120 Turney, J. H., 36
Schifferli, J. E., 745 Stenvinkel, P., 947, 1083 Tuttle, K. R., 918
Stone, J. H., 1040
Schilird, G., 98
Schmid, M., 1146 Stone, S. M., 254 Ubara, Y., 926
Schmidt, K.-H., 150 Stopper, H., 433 Umpleby, S., 36
Schmidt, M., 569 Strain, J. D., 639, 4:E17 Ungkanont, A., 29
Schmidt, R. J., 228 Strawderman, R. L., S1:1 Unsal, I., 140
Schmidt-Nowara, W., 739 Strife, C. F., 1022 Unsal, A., 218
Schmitz, P. G., 92 Sud, K., 6:E25 Uribarri, J., 493
Schneider, B., 247 Sugahara, S., 170 Utsunomiya, Y., 902
Sugar, L., 3:E13
Schultz, J., 464
Sugawara, A., 845
Schulze, D. G., 324 Vamvakas, S., 433
Sugimori, H., 1096
Schwab, S. J., 362, 3:xxxviii Van Es, L. A., 344
Schwab, T. R., 549 Sumino, K., 854 Van Buren, D. H., 869
Scott, R., 464 Sunder-Plassmann, G., $2:25 Van der Woude, F. J., 364
Scott-Douglas, N. W., 669 Suzuki, H., 170 Van Melle, G., 2:E3
Scrivo, D., 445 Swaminathan, S., 6:E25 Vardinon, N., 146
Seigle, R. L., 184 Swartz, R. D., 424 Vega-Diaz, N., 508
Semenyuk, L., 464 Szezech, L.,.$2:5 Verburgh, C. A., 344
Sfriso, A., 1002 Szeto, C.-C., 235, 514, 3:E12, 1056, Viberti, GC., 1139
1132
Shapiro, J. I., 304 Vidiella, J., 264
Sharma, A. P., 646 Villa, M., 618
Sharma, K., 4:E16, 818 Tabata, T., 832 Volpini, R., 328
Sharma, R. K., 646 Tagami, T., 926 Vonesh, E. F., 713
Sharp, C. K., 863 Taguma, Y., 894 Vychytil, A., 247
Shaver, M. J., 942 Takemoto, F., 926
Shayakul, C., 374 Takemura, T., 1016 Waiser, J., 556, 3:E9
Shemin, D., 14 Tam, J. S., 1132 Wang, A. Y. M., 3:E12
Sherman, R. A., 972 Tanaka, I., 845 Wang, T., 1083
Sherrard, D. J., 688 Tanaka, K., 845 Wang, X.-Q., 706
Sheth, A., 5:E22 Tanaka, R., 289 Warnock, D. G., 579
Shickle, L. M., 694 Tanaka, S., 926 Wassermann, A., 445
Shih, D., 713 Tang, S., 380 Watkins, S. L., 651
Shimatsu, A., 845 Tanimu, D., 55 Weaver, C. M., 324
Shinn, C., 304 Taylor, C. A., TIT, 657 Webb, R. L., S1:1
Shinozaki, M., 279 Tedeschi, P. J., S1:1 Weber, J., 678
Shiozawa, S., 289 Terreros, D., 549 Wechsler, B., 633
SUBJECT INDEX
Weir, M. R., 1 Wong, T. Y. H., 235, 514, 1056, 1132 Yokota, S., 228
Weisberg, L. S., 1010 Woodle, E. S., 69, 540 Yoshikawa, N., 289, 854
Weiss, N. S., 688 Woodrow, G., 3 Yoshioka, K., 1016
Werner, D., 2:E3 Work, J., 61, 478, 597 Young, E. W., S1:1
West, C. D., 1022 Wright, M. J., 36 Yu, A. W. Y., 1056
Wheeler, J. R., S1:1 Yusa, N., 894
Whittier, F., 308 Xia, H., 1065 Yust, I., 146
Williams, R. A., Jr., 549 Xu, H., 289
Wilmer, W. A., 308
Winchester, J. F., 1:xxxvi Yahata, K., 845 Zaltzman, J. S., 3:E13
Wisniewska, J., 663 Yamada, A., 926 Zamorani, E., 1048
Wit, E.-J. C., 69 Yamamoto, S., 1016 Zeligman, B. E., 863
Wolach, B., 1129 Yamamoto, T., 170 Zennaro, C., 1048
Wolf, B., 875 Yan, G., 493 Zhang, J.-Z., 189
Wolf, G., 5:E20 Yang, D.-H., 259 Zibari, G. B., 61
Wolfe, R. A., S1:1 Yip, P. S., 6:E26 Zimmerman, S. W., 657
Wong, 355 Yokota, M., 926 Ziyadeh, F. N., 818
Wong, R. W. S., 315 Yokota, N., 114 Zucchelli, P., 530
SUBJECT INDEX
Articles under the rubric Of Nephrology and Nephrologists are referred to by
journal number, a colon, and page numbers.
Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal
number, a colon, the letter E, and a number.
Page references to Supplement | (August 1999) and Supplement 2 (October 1999)
are preceded, respectively, by S1: and S82:.
AAs (amino acids), reabsorption of, in pediatric FS second- Acidosis
ary to chemotherapy, 100 glucocorticoids in, 960-965
Abbreviations, 1999 USRDS ADR, S1:7-8
and nutritional status of ESRD patients on HD, 493-499
ABD (aluminum-related bone disease), see Renal osteodys-
ACKD (acquired cystic kidney disease) in ESRD children
trophy in ESRD patients on HD
on CAPD, 242-246
Abdominal pain, persistent, and prevalence of active CMV
Acknowledgment for use of USRDS data, $1:35
in GI tract of RTx recipients, 65-68
Acquired cystic kidney disease (ACKD) in ESRD children
ABO blood group, and RTx for ESRD, USRDS 1999 ADR
on, $1:98 on CAPD, 242-246
Abstracts citing USRDS data, $1:29 Actin, see Smooth muscle actin; a-Smooth muscle actin
Abusive end-stage renal disease patients, see Physician’s Active cytomegalovirus (CMV) infection in GI tract of RTx
duties to abusive, aggressive, or disruptive ESRD recipients, persistent abdominal pain, 65-68
patients on HD Acute c-anti-neutrophil cytoplasmic-positive vasculitis, MMF
Acceptance into ESRD therapy, $1:162-164 for, 3:E9
Access, vascular, see Vascular access, HD Acute interstitial nephritis (AIN), 4:E14
Access to RTx, USRDS 1999 ADR on, S1:96-98 drug-induced renal allograft, histopathology and course
executive summary of, S1:15-16 of, 540-548
by pediatric patients, S1:109-110
Acute rejection
ACE, see: ACE gene; Angiotensin-converting enzyme; An-
pulse methylprednisolone for, time course of response to,
giotensin-converting enzyme inhibitor(s) 304-307
ACE gene
racial disparities in, 709
in NIDDM siblings, MA and, 1002-1009
see also Polymorphism of ACE gene Acute renal failure (ARF)
Acid/base homeostasis bedside renal biopsy for, 956
effects of Pi replacement for hypophosphatemia on, in CRRT of, see Acute renal failure, CRRT of
RTx recipients, 875-883 due to immersion in seawater polluted by diesel oil, 6:E26
see also pH due to paradoxical embolism, 752-755
1166 SUBJECT INDEX
neonatal, due to transplacental transfer of nephrotoxic Age
paraprotein, exchange transfusion for, 1129-1131 of ADPKD patients with colonic diverticular disease, 865
renal AED with, gallium-67 uptake in, 161-165 of bedside renal biopsy patients, 956
with Rosai-Dorfman disease, 3:E12 of CAD patients, 920, 922
streptococcal toxic shock syndrome with desquamating of chronic GN patients, 115
erythema and, 150-154 of DM patients, see Age of DM patients
see also Neutrophils in ARF of early renal disease patients, LVH and, 127, 129, 131
Acute renal failure (ARF), CRRT of of ESRD patients, see Age of ESRD patients on RRT
convective clearances with, at various dialysate and ultra- of FS patients, 99
filtration flow rates, 486-492 of FSGS patients, 620
see also Diffusive clearances, and CRRT of ARF of HTN patients, see Age of HTN patients
Acute tubular necrosis (ATN) of hypokalemic patients, 109
in diabetes mellitus, HD for, 1010-1015 of IgAN patients, see Age of IgAN patients
spontaneous graft rupture due to, 355-358 of IMN patients, 523
Acute vision loss with pediatric ARPKD, 1125-1128 of LN patients, 317, 319
Acylcarnitine, serum, L-carnitine effects on, 682, 685 of MGN and LMGN patients, 86
Address of USRDS site on World Wide Web, $1:25 of MPGN patients, 1024
Adenosine triphosphatase (ATPase) in pediatric FS second- of nephrotic-range proteinuria patients, 136, 137
ary to chemotherapy, 101 of NS patients, 612
Adequacy of dialysis of POEMS syndrome patients, 634
of CAPD, independent effects of RRF and, on nutritional of proliferative GN patients, DSG effects and, 895
status of CAPD patients, 1056-1064 of recurrent Goodpasture’s syndrome, 554
on prolonged slow HD, 599-601 of severe ARF patients, 426, 428, 429
of TINU syndrome patients, 1017
quality improvement of, ESRD Core Indicators Project
Age of DM patients
report on, 1075-1082
with ATN, 1012
see also entries beginning with: Kt/V
and reduced orthostatic cerebral blood flow due to HD,
ADH (antidiuretic hormone), secretion of, and etiology of
1097
IE, 413
Adhesion molecules, role of, in neutrophil-induced renal see also Age of IDDM patients with HTN, captopril and;
Age of NIDDM patients
injury in ARF, 391-393
Age of ESRD patients, USRDS 1999 ADR on
Adjusted death rates of ESRD patients, USRDS 1999 ADR
adjusted first-year death rates by, $1:78
on, $1:75-77, $1:81-82, $1:153-154
causes of mortality by, $1:88-89, $1:91-93
annual, $1:166-171
expected remaining years of life by, $1:84-85, S1:173
first-year, S1:74-80
incidence and prevalence of treated ESRD by, S1:11,
Adjustment
$1:42-45, $1:47-49
standard population for, in USRDS 1999 ADR, 1:153
Medicare expenditures by, $1:132-135
see also Adjustment, rate, in USRDS 1999 ADR
of new ESRD patients, $1:64
Adjustment (standardization), rate, in USRDS 1999 ADR,
patient survival by, $1:172-173
$1:10, $1:152, $1:164-166
of pediatric patients, $1:102-107
see also Adjusted death rates of ESRD patients, USRDS
RRT modality by, S1:57
1999 ADR on
Age of ESRD patients with ADPKD on HD
Admissions, see Hospitalization ACE gene polymorphism and, 275
ADPKD, see Autosomal dominant polycystic kidney disease valvular heart disease and, 266
ADR (Annual Data Report) of USRDS, see United States Age of ESRD patients on HD
Renal Data System, 1998 ADR of; United States and association between acidosis and nutritional status,
Renal Data System, 1999 ADR of 494, 496
Adrenomedullin (AM), plasma and urinary PAMP and, in
with asymptomatic Al-related renal osteodystrophy, 690
chronic GN, 114-119 atherosclerotic vascular disease and, 671, 674
Adverse effects and CVD, 440
of parenteral Fe therapy, $2:44
effects of calcitriol and, on recovery from hypocalcemia,
see also Adverse effects of immunosuppression 456-463
Adverse effects of immunosuppression Fe deficiency diagnosis and, 510
for LN, 525 gentamicin pharmacokinetics and, 223
of prolonged immunosuppression for FSGS, 623 hyperleptinemic, 825, 827
Adynamic bone disease, serum Mg and PTH levels in ESRD leukocyte phagocytic function and viability and, 681
patients on HD and, 43-48 on long-term maintenance HD, genomic damage to lym-
AED (atheroembolic disease), renal, with ARF, gallium-67 phocytes and, 434, 435
uptake in, 161-165 new patients, serum Cr levels and, 696-698
African Americans, see Race race and, and outcome of HD, 723, 728
AFS (Annual Facility Survey), $1:157, $1:159 and relationship between serum Mg and PTH, 44, 45
SUBJECT INDEX 1167
rHuEPO and, 24, 1091 Aggressive end-stage renal disease patients, see Physician’s
SAEG and, 1107 duties to abusive, aggressive, or disruptive ESRD
serial VABF and, 472 patients on HD
see also Age of ESRD patients with ADPKD on HD Aging-related glomerulosclerosis (GS), sex and, 884-888
Age of ESRD patients on PD/CAPD AGN gene in NIDDM siblings, MA and, 1002-1009
with asymptomatic Al-related renal osteodystrophy, 690 Agreement for data release, $1:38-39
Cr generation and, 236 AIN, see Acute interstitial nephritis
and effects of aminoglycosides on RRF, 16, 17 Al, see Aluminum in ESRD patients on HD
of new patients, SCr levels and, 696-698 Albumin
NIDDM and, 516, 517 in LN, 536
nutritional status and, 1058 see also Albumin in ESRD patients; Microalbuminuria;
PET measurement of D/P ratio and, 248 Plasma albumin; Proteinuria
race and, see Age of ESRD patients on PD/CAPD, race Albumin in ESRD patients
and serum, in RRT patients, see Serum albumin in ESRD
see also Age of ESRD patients on PD/CAPD, Fe in; Age patients on RRT
VLPD and, 501
of ESRD patients on PD/CAPD and IP rHuEPO
therapy see also Albumin in ESRD patients on HD; Albumin in
Age of ESRD patients on PD/CAPD, Fe in ESRD patients on PD/CAPD; Prealbumin in ESRD
Fe deficiency diagnosis, 510 Albumin in ESRD patients on HD
Fe status, 31 L-carnitine effects on, 683
Age of ESRD patients on PD/CAPD, leptin and CVD and, 440
hyperleptinemia, 825, 827 Fe deficiency and, 510
and leptin in dialysate, 833 and hyperleptinemia, 826, 827
in new ESRD patients, 696-698
and peritoneal leptin clearance, 840
Age of ESRD patients on PD/CAPD, race and Radix angelicae sinensis effects on, 350
see also Serum albumin in ESRD patients on HD
familial aggregation of ESRD in HIVAN and, 248
and survival, 714, 716 Albumin in ESRD patients on PD/CAPD
Fe deficiency and, 510
Age of ESRD patients on PD/CAPD and IP rHuEPO therapy
and hyperleptinemia, 826, 827
“dry well” dosing technique and, 659
in new ESRD patients, 696-698
pediatric patients on CCPD, 654
race, survival and, 716
Age of ESRD patients on RRT
Aldosterone, see Plasma aldosterone; Renin-aldosterone axis
serum hyaluronan, survival and, 1084, 1085
Alkaline phosphatase (ALP) in ESRD patients on HD
see also Age of ESRD patients on HD; Age of ESRD
with ADPKD, 266
patients on PD/CAPD; Age of RTx recipients
or CAPD, asymptomatic Al-related renal osteodystrophy
Age of HTN patients and, 690
low-renin HTN patients, 581, 584
relationship between serum Mg and PTH and, 44, 45
with MA, 997
Allergic interstitial nephritis (IN), differentiation between
see also Age of IDDM patients with HTN, captopril and
renal AED and, with gallium-67 scan, 161-165
Age of IDDM patients with HTN, captopril and
ALP, see Alkaline phosphatase in ESRD patients on HD
captopril effects on IDDM course, 811 Alpha (a)-smooth muscle actin (a-SMA), expression of
long-term renoprotection with captopril, 820 mesangial cell, and IgAN progression, 902-910
and NS remission with captopril, 310 Alport’s syndrome, X-linked, RT-PCR and direct sequenc-
Age of IgAN patients, 906 ing in detection of COL4A5 gene mutations in, 854-
with PAF-AH gene mutation, 292 862
with TCR Ca gene polymorphism, 282 Alternate-day prednisone, differences between types I and
Age of NIDDM patients III MPGN in response to, 1022-1032
on CAPD, 516, 517 Aluminum (Al) in ESRD patients on HD
with MA, ACE and AGN genes and, 1004 plasma, asymptomatic ABD and, 688-693
Age of RTx recipients and resistance to rHuEPO, 350, 352
with CMV infection, persistent abdominal pain and, 66 serum, and relationship between serum Mg and PTH,
de novo FSGS in renal graft and, 733-735 44, 45
and drug-induced renal graft AIN, 542 see also Renal osteodystrophy in ESRD patients on HD
for FSGS, 1049 AM (adrenomedullin), plasma and urinary PAMP and, in
hypophosphatemic, 876 chronic GN, 114-119
oral CsA versus SGC formulation and, 871 Amino acids (AAs), reabsorption of, in pediatric FS second-
parvovirus B19 infection and PRCA and, 1134, 1135 ary to chemotherapy, 100
quality of life and, 62 Aminoglycosides, effects of, on RRF of PD patients, 14-20
race, RTx outcome and, 708 Amyloidosis
Aggregation size, minimum, in USRDS 1999 ADR analyti- de novo augloid light chain, benign monoclonal gammopa-
cal methods, $1:154 thy turning into, after RTx, 166-169
1168 SUBJECT INDEX
idiopathic myelofibrosis complicated by, 6:E27 Annual renal transplantation (RT; RTx) for ESRD, USRDS
systemic, as primary diagnosis, 138 1999 ADR on, 166-171
Analgesic nephropathy, as primary disease, 435 ANP (atrial natriuretic peptide), proadrenomedullin N-
Analysis files, USRDS terminal 20 as, plasma and urinary AM and, in
for researchers, $1:26-35 chronic GN, 114-119
see also specific analysis files Anterior ischemic optic neuropathy, and acute vision loss in
pediatric ARPKD, 1125-1128
Analytical methods used in USRDS 1999 ADR, S1:18-19,
Antibody(ies)
$1:152-176
for annual mortality, hospitalization, and RTx, $1:166-171 aPL antibody syndrome in RTx for ESRD secondary to
SLE, 1040-1047
database and, see Database, USRDS
monoclonal IgA-« circulating, recurrent Goodpasture’s
to determine causes of mortality, $1:87-88, S1:153
syndrome due to, 549-555, 565-568
for expected remaining years of life, $1:173
Anti-Clq autoantibodies in HUVS and SLE, 745-751
for graft survival, $1:152, $1:173
Antidiuretic hormone (ADH), secretion of, and etiology of
intent-to-treat model in, $1:174-176 IE, 413
lost-to-follow-up classification methods in, $1:160-162 Antigens, see HLA
measurement concepts in, $1:162-164 Anti-glomerular basement membrane (GBM) antibody dis-
for Medicare claims, $1:174 ease, recurrent Goodpasture’s syndrome due to mono-
for patient survival, $1:152, $1:171-173 clonal IgA-« circulating antibody and, 549-555, 565-
for rate adjustment, see Adjustment, rate, in USRDS 1999 568
ADR Anti-glomerular basement membrane (GBM) nephritis,
for treatment modalities, $1:173-174 ANCA-associated pauci-immune GN and, 344-348
what’s new in, $1:152-154 Antihypertensive drugs
PANCAs, see Anti-neutrophil cytoplasmic autoanti- effects of, on MA in hypertension, 984-985
body(ies); c-Anti-neutrophil cytoplasmic autoanti- see also specific classes of antihypertensives; for ex-
body-positive vasculitis ample: Angiotensin-converting enzyme inhibitor(s)
Anemia Anti-neutrophil cytoplasmic autoantibody (ies) (ANCA), anti-
of ESRD, see Iron deficiency in ESRD patients on HD; glomerular basement membrane nephritis and pauci-
Iron deficiency in ESRD patients on PD/CAPD; immune GN associated with, 344-348
Recombinant human erythropoietin for anemic ESRD c-Anti-neutrophil cytoplasmic autoantibody (ANCA)-
patients positive vasculitis, acute, MMF for, 3:E9
and LVH in early renal disease, 125-134 Antioxidants, level of, in ESRD patients on HD treated or
in pediatric ARPKD, acute vision loss and, 1125-1128 not treated with enalapril, 445-455
ANF (atrial natriuretic factor), levels of, and etiology of IE, Antiphospholipid (aPL) antibody syndrome in RTx for ESRD
413-414 secondary to SLE, 1040-1047
Angina in ESRD patients on HD, L-carnitine effects on, 683 Anti-tubular basement membrane (anti-TBM) nephritis, dif-
Angioaccess, HD, see Vascular access, HD ferentiating between partial pediatric FS and, 184-188
Angiography, coronary, in detection of CAD, 918-925 Aortic bacterial endocarditis due § haemolyticus catheter
infection, inverse paradoxical embolism with, in
Angiotensin-converting enzyme (ACE)
chronic HD patient, 338-340, 362-363
activity of serum, in NIDDM ESRD patients on CAPD,
APD, see Automated peritoneal dialysis for ESRD
514-520
aPL (antiphospholipid) antibody syndrome in RTx for ESRD
see also: ACE gene; Angiotensin-converting enzyme in-
secondary to SLE, 1040-1047
hibitor(s)
Aplasia, pure red cell, parvovirus B19 infection causing, in
Angiotensin-converting enzyme (ACE) inhibitor(s)
RTx recipients on tacrolimus, 1132-1136
captopril as, see Captopril
Apnea, sleep, effects of rHuEPO for HD patients on HD,
effects of, on progression of renal disease, 626-632
1089-1095
enalapril as, antioxidant defense level in ESRD patients
Apnea hypoapnea syndrome, reversal of sleep, following
on HD treated or not treated with, 445-455 RTx for ESRD, 739-744
in NIDDM ESRD, 802 Apolipoprotein A (apo-A) in ESRD patients on HD, CVD
PD patients on, RRF and, 16, 17 and, 440, 441
proteinuria and, see Proteinuria, ACE inhibition and Apolipoprotein B (apo-B) in ESRD patients on HD, CVD
Anion gap, and SAHS in RTx recipients, 741 and, 440, 441
Annual adjusted death rate of ESRD patients, USRDS 1999 ARF, see Acute renal failure
ADR on, $1:166-171 Arginine on HD, indices of activity of, 228-234
Annual Data Report of USRDS, see United States Renal ARPKD (autosomal recessive polycystic kidney disease),
Data System, 1998 ADR of; United States Renal Data pediatric, acute vision loss in, 1125-1128
System, 1999 ADR of Arterial embolization, transcatheter renal, in ADPKD pa-
Annual Facility Survey (AFS), $1:157, $1:159 tients with ESRD on HD, 926-931
Annual hospitalization for ESRD, USRDS 1999 ADR on, Arterial pressure, see Blood pressure
$1:166-171 Arteriolar dilation in IE, 408
SUBJECT INDEX 1169
Arteritis, see Polyarteritis nodosa Azathioprine, effects of prednisolone and, on progression of
Asia, incidence and prevalence of treated NIDDM ESRD in, IMN, 521-529
800-801 Azide, tissue exposure to, and glucose transport regulation
Asian Americans, see Race by hypoxia, 189-202
Aspirin, effects of, on heparin requirements of ESRD pa-
tients on HD, 38 Bacteremia associated with tunneled, cuffed, permanent HD
Assessment of abusive and/or aggressive patients and their catheters, 1114-1124
noncompliance, 781-782 Bacterial endocarditis, aortic, due S$ haemolyticus catheter
Asymmetry, renal, in children with ADPKD, 639-645, 4:E17 infection, inverse paradoxical embolism with, in
Asymptomatic aluminum-related bone disease (ABD) in chronic HD patient, 338-340, 362-363
ESRD patients on HD or CAPD, 688-693 Bacterial virulence, Fe effects on, $2:48-49
AT] receptor gene, and scarring in VUR, 140-145 Bartter’s syndrome, Gitelman’s syndrome as subtype of,
ATG gene, and scarring in VUR, 140-145 R642C missense mutation of TSC gene in, 845-853
Atheroembolic disease (AED), renal, with ARF, gallium-67 BD (bullous dermatoses) in ESRD patients on CAPD,
uptake in, 161-165 155-160
Atherosclerosis, MA in TNH and, 996-1001 Bedside renal biopsy, ultrasound guidance for, 955-959
Atherosclerotic vascular disease, hyperhomocyst(e)nemia Benign monoclonal gammopathy turning to de novo augloid
and prevalence of, in ESRD patients on HD, 669-677 light chain amyloidosis after RTx, 166-169
Berger’s disease, see IgA nephropathy
Atlas of renal pathology, 1:E1, 2:El, 3:E7, 4:E14, 5:E18,
6:E23 Beta (8) cells, function of, in NIDDM patients on CAPD for
ESRD, homeostasis model analysis of, 514-520
ATN, see Acute tubular necrosis
ATPase (adenosine triphosphatase) in pediatric FS second- Beta,-microglobulin, see B.-Microglobulin
ary to chemotherapy, 101 BF (blood flow), see Vascular access blood flow, HD
Atrial natriuretic factor (ANF), levels of, and etiology of IE, Bicarbonate, see NaHCO,
413-414 Bilateral hydronephrosis without obstruction, reversibility
of, in HBV infection-associated PAN, 3:E11
Atrial natriuretic peptide (ANP), proadrenomedullin N-
Bilateral renal infarction secondary to paradoxical embo-
terminal 20 as, plasma and urinary AM and, in
lism, 752-755
chronic GN, 114-119
Bilirubin, total, in severe ARF, 427-430
Augloid light chain amyloidosis, de novo, benign monoclo-
Bioavailability of oral CsA versus SGC formulation, 869-874
nal gammopathy turning into, after RTx, 166-169
Biochemistry
Autoantibodies
of NIDDM patients on CAPD for ESRD, relationship
anti-Clq, in HUVS and SLE, 745-751
between insulin requirements and, 514-520
see also Anti-neutrophil cytoplasmic autoantibody(ies);
see also specific biochemical data
c-Anti-neutrophil cytoplasmic autoantibody-positive
Biocompatible membranes, see High-flux biocompatible
vasculitis membranes, HD for ESRD with
Automated literature search in online features of AJKD,
Biological marker of Fe status, see Serum ferritin
1137-1138
Biomedical Scientific Advisory Committee (B-SAC),
Automated peritoneal dialysis (APD) for ESRD USRDS, S1:5
aminoglycosides and RRF on, 17
Biopsy
influence of preceding exchange on PET results on, bone, of renal osteodystrophy, 4:1x
247-253 see also Histopathology; Renal biopsy
Automated spring-loaded gun device, percutaneous renal
Black Americans, see Race
biopsy using ultrasound-guided, effects of, on bleed-
Bleeding due to percutaneous renal biopsy, effects of using
ing, and implications for early hospital discharge, ultrasound-guided automated spring-loaded gun de-
92-97
vice on, 92-97
Autosomal dominant polycystic kidney disease (ADPKD) Blood flow
without ESRD, colonic diverticular disease with, 863-868 velocity of orthostatic cerebral, HD for diabetes mellitus
extrarenal manifestations of, 6: xlv-xlviii and reduction of, 1096-1104
see also Autosomal dominant polycystic kidney disease, see also Vascular access blood flow, HD
ESRD patients on HD with; Cyst(s) in ADPKD Blood group, ABO, and RTx for ESRD, USRDS 1999 ADR
Autosomal dominant polycystic kidney disease (ADPKD), on, $1:98
ESRD patients on HD with, 264-278 Blood pressure (BP)
ACE gene polymorphism and progression of renal failure in, in chronic GN, 115
273-278 in doxorubicin-induced nephropathy, NaHCO; effects on,
echocardiography of cardiac complications in, 264-272 331, 334
transcatheter renal arterial embolization in, 926-931 in ESRD patients on CAPD, NIDDM and, 516, 517, 802;
Autosomal recessive polycystic kidney disease (ARPKD), see also Blood pressure of ESRD patients on HD
pediatric, acute vision loss in, 1125-1128 in Gitelman’s syndrome, 846
Availability of kidneys, RTx and, USRDS 1999 ADR on, in IE, 416
$1:95-96 in IgAN, 282, 906
1170 SUBJECT INDEX
in IMN, 523 Body weight (BW) of DM patients
in MGN and LMGN, 86 on HD, and orthostatic hypotension and, 1100
in proliferative GN, DSG effects on, 895 and remission of NS with captopril in IDDM, 310
and remission of NS with captopril in IDDM, 310 Body weight (BW) of ESRD patients on HD
in severe ARF, 427-430 acidosis, nutritional status and, 496
see also Hypertension; Hypotension and Fe status, 31
Blood pressure (BP) of ESRD patients on HD gentamicin pharmacokinetics and, 223
with ADPKD, valvular heart disease and, 266 and HTN, 220
and CVD, 440, 441 race and, and HD outcome, 728
intradialytic serial VABF and, 471-477 SAECG and, 1108
in NIDDM ESRD, 802 Body weight (BW) of ESRD patients on PD/CAPD
on prolonged slow HD, 602-603 Cr generation and, 236
SAECG and, 1108 effects of aminoglycosides on RRF and, 16, 17
venous, of HD access grafts, monitoring of, at high blood and IP rHuEPO administration, 659
flow, and graft failure prediction, 212-217 NIDDM and, 516, 517
Blood urea nitrogen, see BUN nutritional status and, 1058
BMI, see Body mass index race, survival and, 715
Body composition of ESRD patients on VLPD, DEXA in Bone disease, see Renal osteodystrophy in ESRD patients
assessment of outcome of, 500-507 on HD
Body fat, total, in ESRD patients, VLPD and, 501, 503-504 Bone marrow of ESRD patients on CAPD, Fe content of,
Body mass index (BMI) 29-35
of CAD patients, 920 BP, see Blood pressure
of ESRD patients, see Body mass index of ESRD patients Breast cancer, scleroderma renal crisis and sclerosis associ-
of HTN patients, see Body mass index of HTN patients ated with, 937-941
of NIDDM patients with MA, ACE and AGN genes and, Bromocriptine in IE, 416
1004 B-SAC (Biomedical Scientific Advisory Committee),
Body mass index (BMI) of ESRD patients USRDS, S1:5
on RRT, serum hyaluronan and survival and, 1084; see Bullous dermatoses (BD) in ESRD patients on CAPD,
also Body mass index of ESRD patients on HD; 155-160
Body mass index of ESRD patients on PD/CAPD BUN (blood urea nitrogen)
VLPD and, 501 and bleeding due to percutaneous renal biopsy, 93
Body mass index (BMI) of ESRD patients on HD in DM patients on HD, orthostatic hypotension and, 1100
acidosis, nutritional status and, 495, 496 in MGN and LMGN, 86
cardiac complications in patients with ADPKD, 266 in nephrotic-range proteinuria, 136, 137
and hyperleptinemia, 826, 827 in proliferative GN, DSG effects on, 895
of new ESRD patients, 696-698 and RTx, 741
Body mass index (BMI) of ESRD patients on PD/CAPD in severe ARF, 427-430
Cr generation and, 236 see also BUN in ESRD patients on HD; BUN in ESRD
of new ESRD patients, 696-698 patients on PD/CAPD
nutritional status and, 1058 BUN (blood urea nitrogen) in ESRD patients on HD
see also Body mass index of ESRD patients on PD/ acidosis, nutritional status and, 495, 496
CAPD, leptin and gentamicin pharmacokinetics and, 223
Body mass index (BMI) of ESRD patients on PD/CAPD, in new ESRD patients, 696-698
leptin and in pediatric ESRD patients, 53
with hyperleptinemia, 826-828 BUN (blood urea nitrogen) in ESRD patients on PD/CAPD
and leptin in dialysate, 833, 834 in new ESRD patients, 696-698
and peritoneal leptin clearance, 840 race, survival and, 715
Body mass index (BMI) of HTN patients BW, see Body weight
with low-renin HTN, 581-584
with MA, 997 C difficile (Clostridium difficile), IgAN associated with,
Body temperature in severe ARF, 427-430 4:E16
Body weight (BW) Clq (complement Iq), autoantibodies against, in HUVS and
of DM patients, see Body weight of DM patients SLE, 745-751
of ESRD patients, VLPD and, 501; see also Body weight C3 (complement 3)
of ESRD patients on HD; Body weight of ESRD serum, in LN, 317
patients on PD/CAPD in types I and III MPGN, 1022-1032
of hypokalemic patients, 109 C4 (complement 4), serum, in LN, 317
of hypophosphatemic RTx recipients, 876 Ca (calcium)
of IE patients, morning-evening differences in, 416 in DM patients on HD, and orthostatic hypotension, 1100
of renal insufficiency patients, LVH and, 127, 129, 131 in nephrotic-range proteinuria, 136, 137
of severe ARF patients, 427-430 in recurrent Goodpasture’s syndrome, 551